Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: Neurofibromatosis 2 natural history consortium

Otology and Neurotology

Volumn 30, Issue 6, 2009, Pages 835-841

  Fisher, Laurel M ^a   Doherty, Joni K ^b   Lev, Michael H ^c   Slattery, William H ^a  

^a HOUSE EAR INSTITUTE   (United States)

^b UNIVERSITY OF SAN DIEGO   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bilateral vestibular schwannoma; Hearing; Mendelian; Neurofibromatosis 2; Tumor growth

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUDIOMETRY; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HEARING; HUMAN; MAJOR CLINICAL STUDY; MALE; NEURILEMOMA; NEUROFIBROMATOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TUMOR GROWTH; TUMOR VOLUME; VESTIBULAR SCHWANNOMA;

ADOLESCENT; ADULT; AGED; AUDIOMETRY, PURE-TONE; CHILD; CHILD, PRESCHOOL; CRANIAL NERVE NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENES, NEUROFIBROMATOSIS 2; GENOTYPE; HEARING LOSS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 2; NEUROFIBROMIN 2; NEUROMA, ACOUSTIC; PHENOTYPE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 69749119143     PISSN: 15317129     EISSN: 15374505     Source Type: Journal    
DOI: 10.1097/MAO.0b013e3181b2364c     Document Type: Article

References (32)

1. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, USA, July 13-15, 1987. Neurofibromatosis 1988;1:172-178
2. Rouleau GA, Merel P, Lutchman M, et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2. Nature 1993;363:515-521 (Pubitemid 23186636)
3. Trofatter JA, MacCollin MM, Rutter JL, et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993;72:791-800. (Pubitemid 23093886)
4. Ruttledge MH, Anderman AA, Phelan CM, et al. Type of mutation in the neurofibromatosis type 2 gene(NF2) frequently determines severity of disease. Am J Hum Genet 1996;59:331-342
5. Evans DGR, Trueman L, Wallace A, et al. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. J Med Genet 1998;35:450-455 (Pubitemid 28252151)
6. Bourn D, Carter A, Evans DGR, Goodship J, Coakham H, Strachan T. A mutation in the Neurofibromatosis Type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in 2 unrelated individuals. Am J Hum Genet 1994;55:69-73. (Pubitemid 24242384)
7. Parry DM, Eldridge R, Kaiser-Kupfer MI, et al. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet 1994;52: 450-461 (Pubitemid 24298996)
8. Dipple K, McCabe E. Phenotypes of patients with "simple" Mendelian disorders are complex traits: thresholds, modifiers, and systems dynamics. Am J Hum Genet 2000a;66:1729-1735 (Pubitemid 30480080)
9. Dipple K, McCabe E. Modifier genes convert "simple" Mendelian disorders to complex traits. Mol Genet and Metab 2000b;71:43-50.
10. Brackmann DE, Kwartler JA. A review of acoustic tumors: 1983-1988. Am J Otol 1990;11:216-232
11. Selesnick SH, Jackler RK, Pitts LW. The changing clinical presentation of acoustic tumors in the MRI era. Laryngoscope 1993;103: 431-436
12. Slattery WH III, Fisher LM, Iqbal Z, Oppenheimer M. Vestibular schwannoma growth rates in Neurofibromatosis type 2 Natural History Consortium subjects. Otol Neurotol 2004;25:811-817 (Pubitemid 39223261)
13. Rosenburg SI. Natural history of acoustic neuromas. Laryngoscope 2000;110:497-508.
14. Stipkovits EM, Graamans K, Vasbinder GB, Van Dijk JE, Beek FJ. Assessment of vestibular schwannoma growth: application of a new measuring protocol to the results of a longitudinal study. Ann Otol Rhinol Laryngol 2001;110:326-330 (Pubitemid 32319800)
15. Linthicum FH Jr, Brackmann DE. Bilateral acoustic tumors. Arch Otolaryngol 1980;106:729-733
16. Masuda A, Fisher LM, Oppenheimer ML, et al. Hearing changes after diagnosis in Neurofibromatosis type 2. Otol Neurotol 2004; 25:150-154 (Pubitemid 39079843)
17. Massick DD, Welling DB, Dodson EE, et al. Tumor growth and audiometric change in vestibular schwannomas managed conservatively. Laryngoscope 2000;110:1843-1849
18. Slattery W, Fisher LM, Yoon G, Sorensen G, Lev MH. Magnetic resonance imaging scanner reliability for measuring changes in vestibular schwannoma size. Otol Neurotol 2003;24:666-670 (Pubitemid 36886286)
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216 (Pubitemid 30099779)
20. Slattery WH, Connell S, Fisher LM, Iqbal Z, Lev MH, Go JL. MRI evaluation of neorofibromatosis 2 patients: a standardized approach for accuracy in interpretation. Otol Neurotol 2005;26:733-740 (Pubitemid 41026105)
21. Kluwe L, Mautner V. Mosaicism in sporadic Neurofibromatosis 2 patients. Hum Med Genet 1998;7:2051-2055
22. Abaza MM, Makariou E, Armstrong M, Lalwani AK. Growth rate characteristics of acoustic neuromas associated with Neurofibromatosis type 2. Laryngoscope 1996;106:694-699 (Pubitemid 26184043)
23. Mautner V-F, Baser ME, Thakkar SD, et al. Vestibular schwannoma growth in patients with neurofibromatosis type 2: a longitudinal study. J Neurosurg 2002;96:223-228 (Pubitemid 34230234)
24. Baser ME, Marakiou EV, Parry DM. Predictors of vestibular schwannoma growth in patients with neurofibromatosis type 2. J Neurosurg 2002;96:217-222 (Pubitemid 34230233)
25. Ogden CA, Rich ME, Schork NJ, et al. Candidate genes, pathways and mechanisms for bipolar (manic-depressive) and related disorders: an expanded convergent functional genomics approach. Molecular Psychiatry 2004;9:1007-1029
26. Scriver C. After the genome - the phenome? J Inherit Metab Dis 2004;27:305-317.
27. Hansen MR, Linthicum FH Jr. Expression of neuregulin and activation of erbB receptors in vestibular schwannomas: possible autocrine loop stimulation. Otol Neurotol 2004;25:155-159
28. Labit-Bouvier C, Crebassa B, Bouvier C, et al. Clinicopathologic growth factors in vestibular schwannomas: a morphologic and immunohistochemical study on 69 tumors. Acta Otolaryngol 2000; 120:950-954 (Pubitemid 32738494)
29. Saito K, Kato M, Susaki N, et al. Expression of Ki-67 antigen and vascular endothelial growth factor in sporadic and neurofibromatosis type 2-associated schwannomas. Clin Neuropathol 2003; 22:30-34 (Pubitemid 36152122)
30. Charabi S. Acoustic neuroma/vestibular schwannoma in vivo and in vitro growth models. A clinical and experimental study. Acta Otolaryngol Suppl 1997;530:1-27.
31. Cayé-Thomasen P, Baandrup L, Jacobsen GK, et al. Immunohistochemical demonstration of VEGF in vestibular schwannomas correlates to tumor growth rate. Laryngoscope 2003;113: 2129-2134
32. Cayé-Thomasen P, Werther K, Nalla A, et al. VEGF and VEGF Receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol 2005;26:98-101. (Pubitemid 40130217)